Bio-IT World | As the cost of sequencing continues to freefall, the challenge of solving the data analysis and storage problems becomes more pressing. But those issues are nothing compared to the challenge facing the clinical community who are seeking to mine the genome for clinically actionable information—what one respected clinical geneticist calls “the $1 million interpretation.”
|
Groups of clinicians, academics, and some savvy software companies are crafting the tools and ecosystem to make medical sense of the sequence. By Kevin Davies September 28, 2010 | It is doubtful that the scientists and physicians who first started
|
Nov. 12, 2008 | The economic environment is terrible—full stop. The financial devastation we are suffering with the echo boom of the credit crisis will be felt for many years.
|
Grappling with the Next-Gen Data Glut
|
Nov. 6, 2008 | The economic environment is terrible—full stop. The financial devastation we are suffering with the echo boom of the credit crisis will be felt for many years.
|
Bio-IT World Weekly Update - Sept. 30, 2008
|
Studies Suggest Cancer Pathways Are Best Targets
|
Bio-IT World | It has been shown over the many investment cycles that some of the most compelling companies are born in the most turbulent of economic times. As bad as it is now, economic cycles do just that – cycle.
|
Big Blue continues to weather industry storms and come out on top. By John Russell Sept. 5, 2008 | Trying to describe in a single story the full scope of IBM’s Life Sciences and Healthcare activities and related work being done
|
Cover Story The Platform Diet Nicolas Saccomano, Pfizer's head of technology for R+D talks about dropping attrition rates, finding new talent, curbing the company's appetite for new tools - and empowering scientists with higher-quality data. Tackling cGMP; A Better Way to Innovate PHARMA-IT - Spe
|
Dec. 17, 2007 | Venture capitalists need to go back to school. It is that simple. Some of our best, most innovative, most promising investment opportunities are coming from campuses of many of the universities in our back yards. In fact entrepreneurs would also be well-served going back to school. In addition to
|
Tuesday, June 5, 2007 | Bio-ITWorld.com | Archives | Advertising | Your Account | CHI Conferences | Subscribe |
|
May 15, 2007 | Perhaps the single greatest task of being a venture capitalist involves recruiting for our portfolio companies. Those who are very good at it build very successful companies and serve as a real source of value to the entrepreneurs we back. An important aspect of recruiting is being conversant with
|
Tuesday, April 10, 2007 | Bio-ITWorld.com | Archives | Advertising | Your Account | CHI Conferences | Subscribe |
|
March 12, 2007 | A few months ago my firm invested in two diagnostic companies and we were very much not alone. In the first half of 2006, nearly $300 million of venture capital flowed into the United States and European diagnostics industries, which greatly eclipsed the amount invested in 2005. Anecdotally the
|
Predictive Biosciences announced today it has secured $10 million in Series A financing. Highland Capital Partners and IDG Ventures Boston co-led the investment in the company, which was jointly founded by the investors, leading entrepreneurs and internationally renowned scientists. In conjunction with the funding,
|
What Use Is the $1000 Genome?
Michael A. Greeley
Last month, at an industry conference, I heard a number of distinguished speakers discuss the prospects for the $1,000 genome and the critical path to get there. Everyone in the audience seemed excited and asked many compelling questions to sort out
|
Shaping a Web That Better Serves Humanity
What Use Is the $1000 Genome?
Abbott Buys Kos Pharma for $3.7 Billion
Tuesday, Nov 7, 2006
Bio-IT World News Bulletin Subscribe Advertising Your Account
|
Oct. 16, 2006 | Last month, at an industry conference, I heard a number of distinguished speakers discuss the prospects for the $1,000 genome and the critical path to get there. Everyone in the audience seemed excited and asked many compelling questions to sort out exactly when we would arrive at that point and
|
Science Publishing and the Web
Kevin Davies Earlier this year, Bio-IT World introduced a regular column in the magazine, "Science and the Web," which explores the surging interest in topics such as the Semantic Web, Web 2.0, social networking, wikis, mashups, and so on. These are poised to radically
|